Kezar Life Sciences Inc At PRESIDIO Clinical Trial of KZR-616 Transcript
Good afternoon, everyone, and welcome to Myositis Support and Understanding. We're also known as MSU. We're happy to have you join us on Rare Disease Day today.
My name is Jerry Williams, and I am the Founder and President of Myositis Support and Understanding and I've been living with what my doctors now think is dermatomyositis rather than polymyositis with skin lupus since 2003. MSU is an all-volunteer non-profit organization working to improve the day-to-day lives of myositis patients and caregivers. And one of the ways that we do this is through education about clinical trials and research to help us all better understand and get the information we need to participate in clinical trials and other types of research.
So, join me in welcoming Dr. Mary Katherine Farmer, a rheumatologist and Senior Medical Director at Kezar Life Sciences. Today, she's going to introduce Kezar, KZR-616, and the PRESIDIO clinical study.
Having worked with many of the major pharmaceutical companies,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |